[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339429-105":59,"doc-detail-339429-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","molecular-understanding-and-clinical-outcomes-of-car-t-cell-therapy-in-the-treatment-of-urological-tumors","Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors","","Chimeric antigen receptor engineered T (CAR T) cell therapy has accelerated in oncology, yet its translation to solid tumors remains constrained by immunosuppressive tumor microenvironments, antigen escape, tumor heterogeneity, and limitations in CAR T proliferation, migration, and persistence. Urological tumors represent a common malignancy burden, and review coverage highlights how CAR T targeting of relevant tumor-associated antigens could enable meaningful therapeutic potential. The article summarizes CAR T generation strategies, signaling pathways and targets, and evaluates current advantages, problems, and side effects, proposing future directions based on present gaps.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-understanding-and-clinical-outcomes-of-car-t-cell-therapy-in-the-treatment-of-urological-tumors/339429/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-understanding-and-clinical-outcomes-of-car-t-cell-therapy-in-the-treatment-of-urological-tumors/339429.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is CAR T therapy less developed in solid tumors compared with hematologic malignancies?","Question",{"text":113,"@type":114},"Solid tumors often present immunosuppressive tumor microenvironments, antigen escape, and tumor heterogeneity, along with impaired CAR T cell proliferation, migration, and limited survival time, which collectively restrict effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which urological cancers are discussed as targets for CAR T therapy?",{"text":118,"@type":114},"The review focuses on kidney cancer, bladder cancer, and prostate cancer, considering tumor-associated antigens that support CAR T feasibility for urological tumors.",{"name":120,"@type":111,"acceptedAnswer":121},"What are the key research questions raised about CAR T therapy in urological tumors?",{"text":122,"@type":114},"The article asks how to ensure specificity and personalization, what future directions are most promising, and how safety and efficacy can be improved via broader clinical trials and long-term follow-up.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339429,1790124790,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":46,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","[www.nature.com/cddis](www.nature.com/cddis)  \nREVIEW ARTICLE OPEN   \nMolecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors  \nGong Zhang 1,5, Yuan Wang2,5, Shiyang Lu1,5, Fengzhu Ding3,5, Xia Wang1, Chunming Zhu4 ✉, Yibing Wang 1 ✉ and Kefeng Wang 1 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Chimeric antigen receptor engineered T (CAR T) cell therapy has developed rapidly in recent years, leading to profound developments in oncology, especially for hematologic malignancies. However, given the pressure of immunosuppressive tumor microenvironments, antigen escape, and diverse other factors, its application in solid tumors is less developed. Urinary system tumors are relatively common, accounting for approximately 24% of all new cancers in the United States. CAR T cells have great potential for urinary system tumors. This review summarizes the latest developments of CAR T cell therapy in urinary system tumors, including kidney cancer, bladder cancer, and prostate cancer, and also outlines the various CAR T cell generations and their pathways and targets that have been developed thus far. Finally, the current advantages, problems, and side effects of CAR T cell |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| therapy are discussed in depth, and potential future developments are proposed in view of current shortcomings. |  |  |\n|  | Cell Death and Disease (2024)15:359; [https://doi.org/10.1038/s41419-024-06734-2](https://doi.org/10.1038/s41419-024-06734-2) |  |\n|  |  |  |\n\nFACTS  \n● The latest progress of CAR T cell therapy in urinary system tumors.  \n● The advantages, problems, and side effects of CAR T cell therapy in urinary system tumors.  \n● Mechanism and clinical application of novel immunotherapies in urinary system tumors.  \n● The various studies of CAR T generations and their pathways and targets in urinary system tumors.  \nOPEN QUESTIONS  \n● How to ensure the speciﬁcity and personalization of CAR T cell therapy in patients with urinary system tumors?  \n● What are the possible future directions of CAR T cell therapy in urinary system tumors?  \n● How can the safety and efﬁcacy of CAR T cell therapy be improved through more extensive clinical trials and long-term follow-up?  \nINTRODUCTION  \nAccording to statistics reported in the 2024 edition of CA, a Cancer Journal for Clinicians, urinary system tumors are among the most common malignancies in the United States, accounting for ~24% of all new cancers [1], with a rising incidence recently. In addition  \nto surgery, some traditional treatment options, such as chemotherapy for urothelial carcinoma (UC) or androgen deprivation therapy (ADT) for prostate cancer (PCa), result in suboptimal clinical outcomes. For example, even after radical treatment of PCa, recurrence remains possible, especially for high-risk locally progressive PCa, which has a biochemical recurrence rate of up to 50% within 3 years after surgery [2] . As a result, immunotherapy approaches have gained increased attention in research.  \nAt present, immunotherapy has been applied to multiple types of urinary tumors. In high-risk, non-muscle invasive bladder cancer (NMIBC), Bacille Calmette-Guérin (BCG) has been used to activate the mucosal immune system locally, stimulating an inﬂammatory response, which reduces recurrence risk [3] . In renal cell carcinoma (RCC), systemic interleukin-2 (IL-2) treatment activates the immune system, mainly by stimulating natural killer (NK) cells and T cells to kill tumor cells [4] . In addition, immune checkpoint inhibitors (ICIs), such as those impacting programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1), have been used increasingly to treat urinary system tumors [5] .  \nMore recently, chimeric antigen receptor engineered T cell (CART) therapy, a novel genetically based immunotherapy method, has been applied increasingly in malignancy [6] . CAR T cell therapy h","cbCaiuN34n7CuTYr","https://ap.wps.com/l/cbCaiuN34n7CuTYr","pdf",1096122,"English","# Introduction\n# CAR T Cell Therapy in Tumor Immunotherapy\n# Current CAR T Generations, Pathways, and Targets\n# Advantages, Problems, and Side Effects\n# Future Directions and Open Questions","[{\"question\":\"Why is CAR T therapy less developed in solid tumors compared with hematologic malignancies?\",\"answer\":\"Solid tumors often present immunosuppressive tumor microenvironments, antigen escape, and tumor heterogeneity, along with impaired CAR T cell proliferation, migration, and limited survival time, which collectively restrict effectiveness.\"},{\"question\":\"Which urological cancers are discussed as targets for CAR T therapy?\",\"answer\":\"The review focuses on kidney cancer, bladder cancer, and prostate cancer, considering tumor-associated antigens that support CAR T feasibility for urological tumors.\"},{\"question\":\"What are the key research questions raised about CAR T therapy in urological tumors?\",\"answer\":\"The article asks how to ensure specificity and personalization, what future directions are most promising, and how safety and efficacy can be improved via broader clinical trials and long-term follow-up.\"}]","Molecular understanding and clinical outcomes of CAR T cell therapy in the treatment of urological tumors | PDF",1790030250,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e0e580b525a80ef540d266e9350786a.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07bedf11b48109564482cfa53eac14d5.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8ff64b563626e3ba5fcfa24fc62f3e6.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69553464191c85bd2b587a61e14d7447.webp",980,1301]